Why are non-sedating antihistamines non-sedating?

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 13-18

  Timmerman, H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

CNS side effects; H1 blockade; P glycoprotein; Sedation

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZATADINE; CETIRIZINE; CHLORPHENIRAMINE; DIMETINDENE; DIPHENHYDRAMINE; EPINASTINE; GLYCOPROTEIN P; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; IMIPRAMINE; LORATADINE; MEPYRAMINE; TEMELASTINE; TERFENADINE;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; HYDROGEN BOND; IONIZATION; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; SEDATION;

EID: 0032810664     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.00003.x-i1     Document Type: Article

References (23)

1. 1-receptor antagonists. An EAACI position paper. Allergy 1996; 51:666-75.
2. 3H]mepyramine may predict sedative properties of psychotropic drugs. Eur J Pharmacol 1979; 60:391-6.
3. 1 receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104:270-6.
4. 1 receptors. J Pharm Pharmacol 1979; 31:701-2.
5. 1. Eur J Med Chem 1983; 18:531-4.
6. 3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-selective antihistamine. Eur J Pharmacol 1986; 127:153-5.
7. 1 receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993; 232:199-205.
8. 1-receptor. Proc Natl Acad Sci 1991; 88:11515-9.
9. Banks WA, Audus KL, Davis TP. Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides 1992; 13:1289-94.
10. Reed DJ. Drug transport into the central nervous system. In: Glaser GH, Pentry JK, Woodburn DM, eds. Antiepileptic Drugs: Mechanisms of Action. New York: Raven Press, 1980: 199-205.
11. Hansch C, Björkroth JP, Leo A. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J Pharm Sci 1987; 76:663-87.
12. Overton E. Studien über die Narkose. Jena: Fisher Publishers, 1903.
13. Glave WR, Hansch C. The anesthetic action of volatile aliphatic ethers. J Pharm Sci 1972; 61:589.
14. M values and structure-activity relationships of benzodiazepines J Med Chem 1980; 23:193-201.
15. Timmermans PBMVM, Brands A, Van Zwieten PA. Lipophilicity and brain disposition of clonidine and structurally related imidazolines. Arch Phar 1977; 300:217-26.
16. 1-antihistaminic agents in relation to their central sedative effects. Eur J Pharmac Sci 1994; 2:373-84.
17. 2-receptor histamine antagonists. J Med Chem 1998; 31:656-71.
18. Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77:491-502.
19. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reis M. Terfenadine (Seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993; 45:401-6.
20. Berlin J, King AC, Tutsch K, et al. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma. Invest New Drugs 1994; 12:137-44.
21. Bartus RT, Elliott PJ, Dean RL, et al. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996; 142:14-28.
22. Rapoport SI. Modulation of blood brain barrier permeability. J Drug Targeting 1996; 3:417-25.
23. 1-agonists. J CompAided Mol Design 1995; 9:319-30.